Close Menu

Clovis Oncology

Maintenance treatment with Clovis' rucaparib may be a more tolerable maintenance therapy than chemo in platinum-responsive patients with mutations in BRCA1/2 or PALB2.

Myriad said it will submit a supplementary premarket approval application for its BRACAnalysis CDx, which the FDA originally approved in 2014.

Strata will refer castration-resistant prostate cancer patients with BRCA and ATM mutations for potential enrollment in Clovis' Rubraca studies.

FDA clearance of the first NGS companion diagnostic paves the way for other comprehensive genomic profiling tests, but Foundation will have to educate docs on the benefits of its test.

The test is approved to identify patients who harbor BRCA mutations and are therefore more likely to respond to Clovis Oncology's ovarian cancer drug Rubraca.

Clovis hopes Sysmex's BEAMing test will work better than FFPE tests to identify candidates for treatment with rociletinib, its investigational EGFR inhibitor.

Interim data showed 40 percent of patients with a DNA repair signature experienced tumor shrinkage when treated with the drug.

Originally published August 8.
NEW YORK (GenomeWeb) – Clovis Oncology this week reported that the company had incurred a net loss for the second quarter of $34.8 million, compared to $19.3 million in the second quarter of 2013.

FDA Clears Sequenom's IMPACT Dx to Aid Thrombophilia Diagnosis
The US Food and Drug Administration this week cleared Sequenom's IMPACT Dx Factor V Leiden and Factor II genotyping test.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.